PROM1 and glioblastoma: In this context, CD133 is a widely accepted marker of GSCs, and when CD133+ GSCs and CD133-GBM cells are compared in terms of chemoresistance, it has been shown that CD133+ GSCs demonstrate more chemoresistance than CD133-GBM cells.